Inventiva SA ADR IVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.58
- Day Range
- $3.49–3.63
- 52-Week Range
- $2.85–7.98
- Bid/Ask
- $3.50 / $3.73
- Shares Outstanding
- 236.22M
- Market Cap
- $833.86M
- Volume/Avg
- 1M / 444,129
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 142.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 77
- Website
- https://www.inventivapharma.com
Valuation
|
Metric
|
IVA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 142.22 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IVA
|
|---|---|
Quick Ratio | 3.10 |
Current Ratio | 3.16 |
Interest Coverage | −9.64 |
Quick Ratio
IVA
Profitability
|
Metric
|
IVA
|
|---|---|
Return on Assets (Normalized) | −105.28% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,862.56% |
Return on Assets
IVA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Yskrdrnk | Gmvtnm | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tjfskvll | Zbbll | $64B | |||
| argenx SE ADR
ARGX
| Pdmqwdymc | Lmzdv | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qdjprybz | Hlryytq | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Kkkkywwcp | Tjcnvg | $24B | |||
| BioNTech SE ADR
BNTX
| Wvkxtbkxx | Gcbs | $23B | |||
| Incyte Corp
INCY
| Fsbyjml | Fzyp | $22B | |||
| Moderna Inc
MRNA
| Hskpbwjvs | Vlvz | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Lhtgpsbv | Ccbg | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Dsfgwgm | Bmys | $13B |
United States